Impact of rs361072 in the Phosphoinositide 3-Kinase p110β Gene on Whole-Body Glucose Metabolism and Subunit Protein Expression in Skeletal Muscle

  1. Allan Vaag1,10
  1. 1Steno Diabetes Center, Gentofte, Denmark;
  2. 2Hagedorn Research Institute, Gentofte, Denmark;
  3. 3Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark;
  4. 4Research Centre for Prevention and Health, Glostrup Hospital, Copenhagen, Denmark;
  5. 5Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark;
  6. 6Department of General Practice, Institute of Public Health, Aarhus University, Aarhus, Denmark;
  7. 7Department of Exercise and Sport Sciences, University of Copenhagen, Copenhagen, Denmark;
  8. 8Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark;
  9. 9Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark;
  10. 10University Hospital MAS, Lund University, Malmo, Sweden.
  1. Corresponding author: Rasmus Ribel-Madsen, rrma{at}


OBJECTIVE Phosphoinositide 3-kinase (PI3K) is a major effector in insulin signaling. rs361072, located in the promoter of the gene (PIK3CB) for the p110β subunit, has previously been found to be associated with homeostasis model assessment for insulin resistance (HOMA-IR) in obese subjects. The aim was to investigate the influence of rs361072 on in vivo glucose metabolism, skeletal muscle PI3K subunit protein levels, and type 2 diabetes.

RESEARCH DESIGN AND METHODS The functional role of rs361072 was studied in 196 Danish healthy adult twins. Peripheral and hepatic insulin sensitivity was assessed by a euglycemic-hyperinsulinemic clamp. Basal and insulin-stimulated biopsies were taken from the vastus lateralis muscle, and tissue p110β and p85α proteins were measured by Western blotting. The genetic association with type 2 diabetes and quantitative metabolic traits was investigated in 9,316 Danes with glucose tolerance ranging from normal to overt type 2 diabetes.

RESULTS While hepatic insulin resistance was similar in the fasting state, carriers of the minor G allele had lower hepatic glucose output (per-allele effect: −16%, Padd = 0.004) during high physiological insulin infusion. rs361072 did not associate with insulin-stimulated peripheral glucose disposal despite a decreased muscle p85α:p110β protein ratio (Padd = 0.03) in G allele carriers. No association with HOMA-IR or type 2 diabetes (odds ratio 1.07, P = 0.5) was identified, and obesity did not interact with rs361072 on these traits.

CONCLUSIONS Our study suggests that the minor G allele of PIK3CB rs361072 associates with decreased muscle p85α:p110β ratio and lower hepatic glucose production at high plasma insulin levels. However, no impact on type 2 diabetes prevalence was found.


  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Received September 12, 2009.
    • Accepted January 18, 2010.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See for details.

| Table of Contents